Intravital biobank and personalized cancer therapy: The correlation with omics

Abstract

Biobanks have played a decisive role in all aspects of the field of cancer, including pathogenesis, diagnosis, prognosis and treatment. The significance of cancer biobanks is epitomized through the appropriate application of various “‐omic” techniques (omics). The mutually motivated relationship between biobanks and omics has intensified the development of cancer research. Human cancer tissues that are maintained in intravital biobanks (or living tissue banks) retain native tumor microenvironment, tissue architecture, hormone responsiveness and cell‐to‐cell signalling properties. Intravital biobanks replicate the structural complexity and heterogeneity of human cancers, making them an ideal platform for preclinical studies. The application of omics with intravital biobanks renders them more active, which makes it possible for the cancer‐related evaluations to be dynamically monitored on a real‐time basis. Integrating intravital biobank and modern omics will provide a useful tool for the discovery and development of new drugs or novel therapeutic strategies. More importantly, intravital biobanks may play an essential role in the creation of meaningful patient‐tailored therapies as for personalized medicine.

Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment

“…The need for long-term storage of cancerous tissues, both reserve samples of original patient specimens and subsequent derived PDX tissue is apparent [15] , [16] . A cryopreserved tissue biobank has implications for several downstream investigations [17] . Cryopreservation is a practical and necessary method for (1) high volume storage of original patient and xenograft derived tissue, (2) rapid access and shipment of tissues for collaborative studies, and (3) availability to rapidly reanimate cryopreserved PDX tumors for in-vivo experimentation [14] , [18] , [19] .…”

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

“…before and after treatment, before each treatment modification or during periods of loco-regional tumor progression as well as at each metastatic episode [ 74 , 75 ]. The possibility of developing intravital biobanks provides an opportunity to test novel therapeutics in in vivo models [ 76 ]. This will be a major contributor to research different biomarkers of resistance and tumor progression [ 76 ].…”

“…The possibility of developing intravital biobanks provides an opportunity to test novel therapeutics in in vivo models [ 76 ]. This will be a major contributor to research different biomarkers of resistance and tumor progression [ 76 ]. The automatic acquisition of digital images of the morphology of the different frozen and/or fixed tumor tissues provides an added value to the biobank, permitting easy access to important information such as the histological type, the results of immunohistochemical analyses, the percentage of tumor cells and the areas of necrosis [ 77 ].…”

The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells

“…The present in vitro study provides an essential base to use synthesized mRNA in in vivo studies and potentially clinical trials. As prospected in our recent review [49], further in vivo studies especially combined with the use of intravital biobanks will lead to the development of clinically meaningful antitumor therapy.…”